In non-small cell lung cancer (NSCLC) cells, treatment with cisplatin induced TROP2 expression accompanied by chemoresistance due to an upregulation of the MAPK signaling pathway [33]. This evidence concerns the gene TACSTD2 and non-small cell lung carcinoma.